Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767431 | 0.90 | FAAH (0.60) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3770860 | 0.88 | FAAH (0.68) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3771002 | 0.86 | FAAH (0.74) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3771924 | 0.84 | FAAH (0.62) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3766125 | 0.84 | FAAH (0.61) | FAAHCSNK1DCSNK1E | |
| SCHEMBL3761029 | 0.83 | FAAH (0.63) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3778528 | 0.83 | FAAH (0.70) | FAAHMAPTMAPK1ALDH1A1LMNA | |
| SCHEMBL3764618 | 0.83 | FAAH (0.63) | FAAHSMN1; SMN2 | |
| SCHEMBL3269230 | 0.82 | FAAH (0.86) | FAAHALDH1A1CSNK1DCSNK1E | |
| SCHEMBL3772080 | 0.81 | FAAH (0.67) | FAAHMAPTMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | claimed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | claimed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885MAPT 3805/4885MAPK1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.